

# Shelby D Reed

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6058603/publications.pdf>

Version: 2024-02-01

113  
papers

4,488  
citations

159585  
30  
h-index

114465  
63  
g-index

117  
all docs

117  
docs citations

117  
times ranked

7648  
citing authors

#	ARTICLE	IF	CITATIONS
1	Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials: The ISPOR RCT-CEA Task Force Report. <i>Value in Health</i> , 2005, 8, 521-533.	0.3	567
2	Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2015, 18, 161-172.	0.3	539
3	Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2009, 12, 409-418.	0.3	395
4	Physical Rehabilitation for Older Patients Hospitalized for Heart Failure. <i>New England Journal of Medicine</i> , 2021, 385, 203-216.	27.0	267
5	Two self-management interventions to improve hypertension control: a randomized trial. <i>Annals of Internal Medicine</i> , 2009, 151, 687-95.	3.9	191
6	The Economic Burden of Allergic Rhinitis. <i>Pharmacoeconomics</i> , 2004, 22, 345-361.	3.3	182
7	The Internal Validity of Discrete Choice Experiment Data: A Testing Tool for Quantitative Assessments. <i>Value in Health</i> , 2019, 22, 157-160.	0.3	124
8	Impact of Cardiovascular Events on Change in Quality of Life and Utilities in Patients After Myocardial Infarction. <i>JACC: Heart Failure</i> , 2014, 2, 159-165.	4.1	91
9	Direct costs of allergic rhinitis in the united states: Estimates from the 1996 medical expenditure panel survey. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 111, 296-300.	2.9	89
10	Conducting economic evaluations alongside multinational clinical trials: Toward a research consensus. <i>American Heart Journal</i> , 2005, 149, 434-443.	2.7	82
11	Cost-effectiveness of imatinib versus interferon- $\gamma$ plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. <i>Cancer</i> , 2004, 101, 2574-2583.	4.1	72
12	Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. <i>American Heart Journal</i> , 2017, 185, 130-139.	2.7	71
13	Patient preferences in advanced or recurrent ovarian cancer. <i>Cancer</i> , 2014, 120, 3651-3659.	4.1	68
14	Depression, quality of life, and medical resource utilization in sickle cell disease. <i>Blood Advances</i> , 2017, 1, 1983-1992.	5.2	66
15	Pain Coping Skills Training for Patients Who Catastrophize About Pain Prior to Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2019, 101, 218-227.	3.0	66
16	COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER. <i>Journal of Urology</i> , 2004, 171, 1537-1542.	0.4	58
17	Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. <i>JAMA Oncology</i> , 2015, 1, 158.	7.1	55
18	Economic Evaluation of Home Blood Pressure Monitoring With or Without Telephonic Behavioral Self-Management in Patients With Hypertension. <i>American Journal of Hypertension</i> , 2010, 23, 142-148.	2.0	52

#	ARTICLE	IF	CITATIONS
19	Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology, 2015, 1, 1098.	7.1	49
20	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2020, 75, 2297-2308.	2.8	48
21	Economic Evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 62 2010, 3, 374-381.	2.2	46
22	Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). American Heart Journal, 2004, 148, 122-128.	2.7	44
23	Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genetics in Medicine, 2013, 15, 203-211.	2.4	44
24	Changes in Initial Treatment for Prostate Cancer Among Medicare Beneficiaries, 1999â€“2007. International Journal of Radiation Oncology Biology Physics, 2012, 82, e781-e786.	0.8	41
25	Updated Estimates of Survival and Cost Effectiveness for Imatinib versus Interferon-?? Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. Pharmacoeconomics, 2008, 26, 435-446.	3.3	38
26	Cost Effectiveness of Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. Journal of Clinical Oncology, 2009, 27, 2185-2191.	1.6	38
27	A phase III randomized three-arm trial of physical therapist delivered pain coping skills training for patients with total knee arthroplasty: the KASTPain protocol. BMC Musculoskeletal Disorders, 2012, 13, 149.	1.9	37
28	Long-term survival estimates for imatinib versus interferon-? plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2004, 101, 2584-2592.	4.1	35
29	Preferences for Health Interventions: Improving Uptake, Adherence, and Efficiency. Patient, 2017, 10, 511-514.	2.7	34
30	Willingness to Accept Trade-Offs Among COVID-19 Cases, Social-Distancing Restrictions, and Economic Impact: A Nationwide US Study. Value in Health, 2020, 23, 1438-1443.	0.3	34
31	Rehabilitation Intervention in Older Patients With Acute HeartÂFailure WithÂPreserved Versus Reduced EjectionÂFraction. JACC: Heart Failure, 2021, 9, 747-757.	4.1	32
32	Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting. Pharmacogenomics, 2014, 15, 1677-1686.	1.3	30
33	Does the Implantable Cardioverter-Defibrillator Benefit VaryÂWith the Estimated Proportional Risk of Sudden Death in Heart Failure Patients?. JACC: Clinical Electrophysiology, 2017, 3, 291-298.	3.2	30
34	Patient Preferences for Features of Health Care Delivery Systems: A Discrete Choice Experiment. Health Services Research, 2016, 51, 704-727.	2.0	29
35	Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. Diabetes, Obesity and Metabolism, 2018, 20, 2379-2388.	4.4	29
36	In-Hospital Resource Use and Medical Costs in the Last Year of Life by Mode of Death (from the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62	1.6	28

#	ARTICLE	IF	CITATIONS
37	COMPARISON OF HOSPITAL COSTING METHODS IN AN ECONOMIC EVALUATION OF A MULTINATIONAL CLINICAL TRIAL. <i>International Journal of Technology Assessment in Health Care</i> , 2003, 19, 396-406.	0.5	27
38	Optimizing delivery of a behavioral pain intervention in cancer patients using a sequential multiple assignment randomized trial SMART. <i>Contemporary Clinical Trials</i> , 2017, 57, 51-57.	1.8	27
39	The burden of noncardiac comorbidities and association with clinical outcomes in an acute heart failure trial—insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1022-1031.	7.1	27
40	Outcomes of inpatients with and without sickle cell disease after high-volume surgical procedures. <i>American Journal of Hematology</i> , 2009, 84, 703-709.	4.1	26
41	Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>American Heart Journal</i> , 2005, 150, 323-329.	2.7	23
42	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. <i>American Journal of Cardiology</i> , 2016, 117, 946-951.	1.6	23
43	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013, 1, 523-530.	4.1	22
44	Economic Evaluation of Zoledronic Acid Versus Pamidronate for the Prevention of Skeletal-Related Events in Metastatic Breast Cancer and Multiple Myeloma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 8-16.	1.3	21
45	Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment. <i>Gynecologic Oncology</i> , 2020, 156, 561-567.	1.4	21
46	Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices. <i>Journal of General Internal Medicine</i> , 2008, 23, 50-56.	2.6	20
47	Staphylococcus aureus infections following knee and hip prosthesis insertion procedures. <i>Antimicrobial Resistance and Infection Control</i> , 2015, 4, 13.	4.1	20
48	Economic Issues and Antibiotic Resistance in the Community. <i>Annals of Pharmacotherapy</i> , 2002, 36, 148-154.	1.9	18
49	Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 113-119.	2.2	17
50	Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer. <i>Cancer</i> , 2019, 125, 4399-4406.	4.1	16
51	Associations Between Seattle Heart Failure Model Scores and Health Utilities: Findings From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2013, 19, 311-316.	1.7	15
52	What is clearance worth? Patients' stated risk tolerance for psoriasis treatments. <i>Journal of Dermatological Treatment</i> , 2017, 28, 709-715.	2.2	15
53	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2019, 42, 1075-1080.	8.6	15
54	Are Videos or Text Better for Describing Attributes in Stated-Preference Surveys?. <i>Patient</i> , 2020, 13, 401-408.	2.7	15

#	ARTICLE	IF	CITATIONS
55	Implementing Lung Cancer Screening Using Low-Dose Computed Tomography: Recommendations From an Expert Panel. <i>Journal of Oncology Practice</i> , 2015, 11, e44-e49.	2.5	14
56	Patients'™ Willingness to Accept Mitral Valve Procedure-Associated Risks Varies Across Severity of Heart Failure Symptoms. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008051.	3.9	14
57	Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia. <i>Current Medical Research and Opinion</i> , 2005, 21, 1527-1533.	1.9	13
58	How Changes In Drug-Safety Regulations Affect The Way Drug And Biotech Companies Invest In Innovation. <i>Health Affairs</i> , 2006, 25, 1309-1317.	5.2	13
59	Preferences of women with epithelial ovarian cancer for aspects of genetic testing. <i>Gynecologic Oncology Research and Practice</i> , 2019, 6, 1.	3.6	13
60	Quantifying Value of Hope. <i>Value in Health</i> , 2021, 24, 1511-1519.	0.3	13
61	Log2Lose: Development and Lessons Learned From a Mobile Technology Weight Loss Intervention. <i>JMIR MHealth and UHealth</i> , 2019, 7, e11972.	3.7	13
62	Economic Evaluation of Weekly Epoetin Alfa versus Biweekly Darbepoetin Alfa for Chemotherapy-Induced Anaemia. <i>Pharmacoeconomics</i> , 2006, 24, 479-494.	3.3	12
63	Effects of Family History and Genetic Polymorphism on the Cost-Effectiveness of Chemoprevention With Finasteride for Prostate Cancer. <i>Journal of Urology</i> , 2011, 185, 841-847.	0.4	12
64	Medical Resource Use, Costs, and Quality of Life in Patients With Acute Decompensated Heart Failure: Findings From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2013, 19, 611-620.	1.7	12
65	Will the Future of Health Care Lead to the End of the Robotic Golden Years?. <i>European Urology</i> , 2014, 65, 325-327.	1.9	12
66	Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). <i>Contemporary Clinical Trials</i> , 2019, 76, 120-131.	1.8	12
67	Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement. <i>American Journal of Hematology</i> , 2010, 85, 79-81.	4.1	11
68	Statistical considerations in economic evaluations: a guide for cardiologists. <i>European Heart Journal</i> , 2014, 35, 1652-1656.	2.2	11
69	Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e120-e129.	2.5	11
70	Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. <i>American Heart Journal</i> , 2006, 152, 500-508.	2.7	10
71	Patient Preferences for Surgical Treatment of Knee Osteoarthritis. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020, 102, 2022-2031.	3.0	10
72	Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. <i>Clinical Transplantation</i> , 2005, 19, 122-129.	1.6	9

#	ARTICLE	IF	CITATIONS
73	A Framework to Evaluate the Cost-Effectiveness of the NADiA ProsVue Slope to Guide Adjuvant Radiotherapy among Men with High-Risk Characteristics Following Prostatectomy for Prostate Cancer. <i>Value in Health</i> , 2014, 17, 545-554.	0.3	9
74	Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 28-37.e2.	1.9	9
75	Impact of financial medication assistance on medication adherence: a systematic review. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 924-935.	0.9	9
76	Factors Influential in the Selection of Radiology Residents in the Post-Step 1 World: A Discrete Choice Experiment. <i>Journal of the American College of Radiology</i> , 2021, 18, 1572-1580.	1.8	9
77	Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer. <i>Journal of Palliative Medicine</i> , 2015, 18, 933-939.	1.1	8
78	Out-of-Pocket Spending for Ambulatory Physical Therapy Services From 2008 to 2012: National Panel Survey. <i>Physical Therapy</i> , 2015, 95, 1680-1691.	2.4	8
79	The economics of PCSK-9 inhibitors. <i>American Heart Journal</i> , 2017, 189, 200-201.	2.7	8
80	Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers. <i>Therapeutic Innovation and Regulatory Science</i> , 2018, 52, 507-513.	1.6	8
81	Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Using a Preemptive Strategy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 568-580.	2.0	8
82	Patient preferences for ketamine-based antidepressant treatments in treatment-resistant depression: Results from a clinical trial and panel. <i>Neurology Psychiatry and Brain Research</i> , 2020, 37, 67-78.	2.0	8
83	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. <i>American Heart Journal</i> , 2015, 170, 951-960.	2.7	7
84	Comparing the Noncomparable: The Need for Equivalence Measures That Make Sense in Health-Economic Evaluations. <i>Value in Health</i> , 2019, 22, 684-692.	0.3	7
85	Behavioral cancer pain intervention using videoconferencing and a mobile application for medically underserved patients: Rationale, design, and methods of a prospective multisite randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2021, 102, 106287.	1.8	7
86	Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008797.	3.9	7
87	Use of clinical algorithms and rapid influenza testing to manage influenza-like illness: a cost-effectiveness analysis in Sri Lanka. <i>BMJ Global Health</i> , 2019, 4, e001291.	4.7	6
88	Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. <i>Value in Health</i> , 2022, 25, 582-594.	0.3	6
89	Associations Between Hemoglobin Level, Resource Use, and Medical Costs in Patients With Heart Failure: Findings From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2012, 18, 784-791.	1.7	5
90	Associations Between Seattle Heart Failure Model Scores and Medical Resource Use and Costs: Findings From HF-ACTION. <i>Journal of Cardiac Failure</i> , 2014, 20, 541-547.	1.7	5

#	ARTICLE	IF	CITATIONS
91	Study protocol for Log2Lose: A feasibility randomized controlled trial to evaluate financial incentives for dietary self-monitoring and interim weight loss in adults with obesity. Contemporary Clinical Trials, 2018, 65, 116-122.	1.8	5
92	Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism, 2018, 20, 1732-1739.	4.4	5
93	Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial. JAMA Cardiology, 2022, 7, 140.	6.1	5
94	Patient preferences pertaining to treatment options for drug-resistant focal epilepsy. Epilepsy and Behavior, 2022, 127, 108529.	1.7	5
95	Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer. Value in Health, 2009, 12, 637-640.	0.3	4
96	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes Care, 2020, 43, 374-381.	8.6	4
97	A randomized feasibility pilot trial of a financial incentives intervention for dietary self-monitoring and weight loss in adults with obesity. Translational Behavioral Medicine, 2021, 11, 954-969.	2.4	4
98	Resource Use and Costs of Treatment With Anticoagulation and Antiplatelet Agents: Results of the WATCH Trial Economic Evaluation. Journal of Cardiac Failure, 2009, 15, 819-827.	1.7	3
99	Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data. Diabetes Care, 2020, 43, 2485-2492.	8.6	3
100	Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer. BMC Cancer, 2021, 21, 824.	2.6	3
101	Resource Use and Expenditures Among Adult Sickle Cell Patients with and without Depression. Blood, 2010, 116, 1534-1534.	1.4	3
102	Update on the Role of Epothilones in Metastatic Breast Cancer. Current Breast Cancer Reports, 2013, 5, 51-56.	1.0	2
103	Developing the Value Proposition for Personalized Medicine. , 2017, , 327-342.		2
104	A Beginner's Guide to Understanding Curative Therapies. Value in Health, 2019, 22, 619-620.	0.3	2
105	The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens. Gynecologic Oncology, 2021, 162, 440-446.	1.4	2
106	Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. Diabetes Research and Clinical Practice, 2022, 183, 109152.	2.8	2
107	Difficulties in applying clinical trial information to the practice setting: Case of a high-cost drug. American Journal of Health-System Pharmacy, 1998, 55, 2409-2414.	1.0	1
108	Is There a Price to Pay for Short-Term Savings in the Clinical Development of New Pharmaceutical Products?. Drug Information Journal, 2007, 41, 491-499.	0.5	1

#	ARTICLE	IF	CITATIONS
109	Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. <i>Clinical Breast Cancer</i> , 2020, 20, 487-494.e1.	2.4	1
110	EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100327.	1.7	1
111	The Association of an Early Hemoglobin Response with Alternative Metrics to Evaluate Treatment Efficacy of Erythropoietic Agents.. <i>Blood</i> , 2004, 104, 234-234.	1.4	1
112	End Point Selection in Acute Decompensated Heart Failure Clinical Trials: Economic End Points. <i>Heart Failure Clinics</i> , 2011, 7, 529-537.	2.1	0
113	In-Hospital Outcomes Among Sickle Cell Patients with Acute Chest Syndrome: Results From a National Database.. <i>Blood</i> , 2009, 114, 1367-1367.	1.4	0